Update Recommendations for Booster Shots
Recommended questions lymphoma patients, survivors, and caregivers can ask their healthcare provider.
News
COVID-19 Vaccine Updates and FAQs
The Lymphoma Research Foundation (LRF) encourages patients, survivors, and their care partners to take information and questions back to their individual health care providers as a way of creating a dialogue and partnership about their lymphoma and treatment.
Hope Forever and a Day
For more than 23 years, Marla Briskman faced her lymphoma—enduring five relapses and six different treatments. What gave her hope? Incredible treatment advancements and the support of family, friends, and her husband and care partner, Rickey.
Care Partner Perspectives: Managing The Responsibilities of Caring for a Loved One
A lymphoma diagnosis not only affects the patient, but their care partners too. LRF Scientific Advisory Board member, Thomas M. Habermann, MD shares some helpful strategies on how to help cope with some of the pressures of being a care partner.
Beyond Barriers
Undeterred by barriers and challenges associated with lymphoma and the
medical field, Dr. Sonali Smith’s work in the clinic and research realms, and
natural-born leadership puts her at the forefront of advancing cures for this
disease.
Growing Stock, Growing Generosity
While many individuals choose to support charities through cash donations,
some donors have adopted a new way of giving in the form of stock gifts.
In Remembrance: Dr. Joseph Bertino
Remembering Joseph R. Bertino, MD, the founding chair of the Lymphoma Research Foundation Scientific Advisory Board.
Three Healthy Ways to Navigate the Internet While Coping with a Lymphoma Diagnosis
Here are some ways lymphoma patients, survivors and caregivers can best navigate the internet for information, emotional and social support needs.
U.S. Food and Drug Administration Approves Ruxolitinib (Jakafi) for Chronic Graft-Versus-Host Disease
Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.
The U.S. Food and Drug Administration Approves Zanubrutinib for Marginal Zone Lymphoma
On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.